zoledronic acid has been researched along with Acute-Phase Reaction in 40 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (2.50) | 18.2507 |
| 2000's | 3 (7.50) | 29.6817 |
| 2010's | 25 (62.50) | 24.3611 |
| 2020's | 11 (27.50) | 2.80 |
| Authors | Studies |
|---|---|
| Black, DM; Cauley, JA; Ewing, SK; Kim, TY; Nakamura, T; Napoli, N; Reid, IR; Schafer, AL; Shiraki, M; Takeuchi, Y | 1 |
| Du, G; Fan, D; Han, G; Li, H; Li, R; Liu, D; Liu, Q; Song, C; Tao, L; Zhang, M | 1 |
| Gong, YQ; Li, C; Lu, K; Shao, JW; Shi, Q | 1 |
| Gong, YQ; Li, C; Lu, K; Shi, Q | 1 |
| Billington, E; Chan, PL; Gamble, GD; Horne, AM; Mellar, A; Murdoch, R; Reid, IR | 1 |
| Gong, YQ; Li, C; Lu, K; Shi, Q; Wu, YM; Zhang, T | 1 |
| Karpuz, S | 1 |
| Akahoshi, S; Asano, K; Fujiwara, S; Fukuhara, S; Fuse, Y; Ikeda, S; Ishikura, T; Katae, Y; Kobayashi, T; Matsumoto, H; Menuki, K; Mizuno, N; Mizuno, T; Nishida, S; Ogawa, T; Okazaki, Y; Okimoto, N; Saito, J; Sakai, A; Yoshioka, T | 1 |
| Chen, FP; Fu, TS; Lin, YC; Lin, YJ | 1 |
| Ichikawa, M; Ikezaki, K; Kamijo, R; Kinoshita, M; Miyamoto, Y; Sasa, K; Sasama, Y; Shirota, T; Suzawa, T; Takimoto, R; Tanaka, M; Yamada, A; Yamamoto, M; Yoshimura, K | 1 |
| Hiraishi, K; Kuroda, T; Nakamura, T; Shiraki, M; Sugimoto, T; Suzuki, H; Takeuchi, Y; Tanaka, S | 1 |
| Ding, Y; Li, SX; Lin, H; Liu, X; Pei, FX; Xue, QY; Yin, F; Zeng, JC; Zhang, C; Zhang, CL; Zhang, Y | 1 |
| Cavaciocchi, F; Ceribelli, A; Crotti, C; De Santis, M; Fabbriciani, G; Marasini, B; Massarotti, M; Selmi, C; Watts, NB | 1 |
| Kavcic Trsinar, Z; Kocjan, T; Smrecnik, M | 1 |
| Igishi, T; Izumi, H; Kodani, M; Makino, H; Nishii-Ito, S; Sakamoto, T; Shimizu, E; Takeda, K; Tanaka, N; Touge, H; Ueda, Y; Yamaguchi, K; Yamasaki, A; Yanai, M | 1 |
| Bastin, S; Bolland, MJ; Gamble, GD; Garratt, E; Horne, AM; Mihov, B; Reid, IR; Stewart, A; Wiessing, KR; Wong, S | 1 |
| Adami, S; Gatti, D; Ortolani, R; Rossini, M; Tripi, G; Troplini, S; Vella, A; Viapiana, O; Zanotti, R | 1 |
| Chen, DC; Chen, Y; Guo, YH; Liu, T; Lu, CY; Wang, Q | 1 |
| Giagourta, I; Karga, H; Kassi, G; Ktena, V; Papaioannou, G; Papamichael, K; Papandroulaki, F; Thanou, S; Triantaphyllopoulou, M; Zapanti, E | 1 |
| Cavaciocchi, F; Ceribelli, A; Crotti, C; De Santis, M; Fabbriciani, G; Generali, E; Massarotti, M; Selmi, C | 1 |
| George, S; Hummel, K; Kaplan, P; Levine, MA; Monk, HM; Weber, DR | 1 |
| Ebeling, PR; Fuller, PJ; Milat, F; Trinh, A; Wong, P | 1 |
| Billington, EO; Gamble, GD; Horne, A; House, M; Maslowski, K; Reid, IR | 1 |
| Buffat, H; Curkovic, I; Lippuner, K; Popp, AW; Popp, PF; Senn, C; Senn, R | 1 |
| Black, DM; Gamble, GD; Lakatos, P; Mesenbrink, P; Reid, IR | 1 |
| Keech, F; May, RJ; McLernon, DJ; Reid, DM; Rogers, MJ; Simpson, WG; Thompson, K; Vinod, K | 1 |
| Carlson, T; Goncalves, J; Kianifard, F; Kriegman, A; Leary, E; Silverman, SL | 1 |
| Anastasilakis, AD; Bisbinas, I; Makras, P; Papapoulos, SE; Polyzos, SA; Sakellariou, GT | 1 |
| Pozzi, S; Raje, N | 1 |
| Adami, S; Fracassi, E; Gatti, D; Ortolani, R; Rossini, M; Vella, A; Viapiana, O | 1 |
| Boon, P; Doré, DA; Jones, G; Laslett, LL; Quinn, SJ; Ryan, E; Winzenberg, TM | 1 |
| Anastasilakis, AD; Ballaouri, I; Bisbinas, I; Delaroudis, S; Gerou, S; Gkiomisi, A; Makras, P; Oikonomou, D; Papapoulos, SE; Polyzos, SA; Sakellariou, GT | 1 |
| Anastasilakis, AD; Bisbinas, I; Delaroudis, S; Gerou, S; Gkiomisi, A; Makras, P; Papadopoulou, E; Polyzos, SA; Sakellariou, GT | 1 |
| Bolland, MJ; Bourke, S; Gamble, GD; Grey, A; Horne, AM; Reid, IR; Wattie, DJ; Wong, S | 1 |
| Eberl, M; Martí, S; Morgan, MP; Moser, B; Sewell, AK; Stone, MD; Turton, J; Welton, JL | 1 |
| Kraenzlin, CA; Kraenzlin, ME; Lardelli, P; Meier, C; Sieber, P | 1 |
| Avvisati, G; Battistoni, F; Borzomati, D; Coppola, R; Dicuonzo, G; Gavasci, M; Rocci, L; Santini, D; Tonini, G; Vincenzi, B | 1 |
| Caraglia, M; Santini, D; Tonini, G; Vincenzi, B | 1 |
| Briody, J; Cowell, CT; Högler, W; Hong, J; Little, DG; McQuade, M; Munns, CF; Rajab, MH | 1 |
| Burckhardt, P; Green, JR; Ibarra de Palacios, P; Kandra, A; Leuenberger, P; Sauty, A; Sitzler, L; Thiébaud, D; Zieschang, J | 1 |
2 review(s) available for zoledronic acid and Acute-Phase Reaction
| Article | Year |
|---|---|
The role of bisphosphonates in multiple myeloma: mechanisms, side effects, and the future.
Topics: Acute-Phase Reaction; Bone Diseases; Diphosphonates; Endothelial Cells; Humans; Imidazoles; Multiple Myeloma; Osteoclasts; Osteocytes; Osteonecrosis; Pamidronate; Practice Guidelines as Topic; Zoledronic Acid | 2011 |
The impact of dietary calcium intake and vitamin D status on the effects of zoledronate.
Topics: Acute-Phase Reaction; Aged; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Calcium, Dietary; Diphosphonates; Dose-Response Relationship, Drug; Female; Food-Drug Interactions; Hip Joint; Humans; Imidazoles; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Randomized Controlled Trials as Topic; Vitamin D; Zoledronic Acid | 2013 |
16 trial(s) available for zoledronic acid and Acute-Phase Reaction
| Article | Year |
|---|---|
The Interaction of Acute-Phase Reaction and Efficacy for Osteoporosis After Zoledronic Acid: HORIZON Pivotal Fracture Trial.
Topics: Acute-Phase Reaction; Bone Density; Bone Density Conservation Agents; Diphosphonates; Female; Hip Fractures; Humans; Imidazoles; Osteoporosis; Zoledronic Acid | 2022 |
Reduction effect of oral pravastatin on the acute phase response to intravenous zoledronic acid: protocol for a real-world prospective, placebo-controlled trial.
Topics: Acute-Phase Reaction; Female; Humans; Meta-Analysis as Topic; Osteoporosis; Pravastatin; Prospective Studies; Randomized Controlled Trials as Topic; Treatment Outcome; Zoledronic Acid | 2022 |
Effect of a Three-Day Course of Dexamethasone on Acute Phase Response Following Treatment With Zoledronate: A Randomized Controlled Trial.
Topics: Acute-Phase Reaction; Dexamethasone; Diphosphonates; Double-Blind Method; Humans; Imidazoles; Zoledronic Acid | 2023 |
Efficacy of non-steroidal anti-inflammatory drugs on zoledronic acid-induced acute-phase reactions: randomized, open-label, Japanese OZ study.
Topics: Acute-Phase Reaction; Aged; Anti-Inflammatory Agents, Non-Steroidal; Asian People; Body Temperature; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Incidence; Japan; Logistic Models; Male; Multivariate Analysis; Odds Ratio; Risk Factors; Treatment Outcome; Zoledronic Acid | 2020 |
Acute Phase Reactions After Intravenous Infusion of Zoledronic Acid in Japanese Patients with Osteoporosis: Sub-analyses of the Phase III ZONE Study.
Topics: Acute-Phase Reaction; Aged; Bone Density; Bone Density Conservation Agents; Diphosphonates; Humans; Imidazoles; Infusions, Intravenous; Japan; Osteoporosis; Zoledronic Acid | 2021 |
Fracture Prevention with Zoledronate in Older Women with Osteopenia.
Topics: Acute-Phase Reaction; Aged; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Remodeling; Calcium; Dietary Supplements; Double-Blind Method; Female; Fractures, Bone; Humans; Infusions, Intravenous; Intention to Treat Analysis; Iritis; Proportional Hazards Models; Zoledronic Acid | 2018 |
Effect of single-dose dexamethasone on acute phase response following zoledronic acid: a randomized controlled trial.
Topics: Acute-Phase Reaction; Administration, Oral; Aged; Aged, 80 and over; Bone Density Conservation Agents; Dexamethasone; Diphosphonates; Double-Blind Method; Female; Glucocorticoids; Humans; Imidazoles; Infusions, Intravenous; Male; Middle Aged; Severity of Illness Index; Zoledronic Acid | 2017 |
Characterization of and risk factors for the acute-phase response after zoledronic acid.
Topics: Acute-Phase Reaction; Aged; Aged, 80 and over; Bone Density Conservation Agents; Diphosphonates; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Imidazoles; Incidence; Osteoporosis, Postmenopausal; Risk Factors; Severity of Illness Index; Time Factors; Zoledronic Acid | 2010 |
Fluvastatin does not prevent the acute-phase response to intravenous zoledronic acid in post-menopausal women.
Topics: Acute-Phase Reaction; Anticholesteremic Agents; Bone Density Conservation Agents; Bone Resorption; Cholesterol; Cytokines; Diphosphonates; Fatty Acids, Monounsaturated; Female; Fluvastatin; Humans; Imidazoles; Indoles; Injections, Intravenous; Middle Aged; Postmenopause; T-Lymphocytes; Zoledronic Acid | 2011 |
Effect of acetaminophen and fluvastatin on post-dose symptoms following infusion of zoledronic acid.
Topics: Acetaminophen; Acute-Phase Reaction; Aged; Antipyretics; Bone Density Conservation Agents; Diphosphonates; Double-Blind Method; Drug Administration Schedule; Fatty Acids, Monounsaturated; Female; Fever; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Imidazoles; Indoles; Inflammation Mediators; Infusions, Intravenous; Middle Aged; Osteoporosis, Postmenopausal; Treatment Outcome; Zoledronic Acid | 2011 |
No effect of rosuvastatin in the zoledronate-induced acute-phase response.
Topics: Acute-Phase Reaction; Aged; Body Temperature; Bone Density Conservation Agents; C-Reactive Protein; Diphosphonates; Dose-Response Relationship, Drug; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Imidazoles; Leukocyte Count; Middle Aged; Osteoporosis, Postmenopausal; Pain Measurement; Prospective Studies; Pyrimidines; Rosuvastatin Calcium; Severity of Illness Index; Sulfonamides; Treatment Outcome; Zoledronic Acid | 2011 |
Zoledronic acid reduces knee pain and bone marrow lesions over 1 year: a randomised controlled trial.
Topics: Acute-Phase Reaction; Aged; Arthralgia; Bone Density Conservation Agents; Bone Marrow Diseases; Diphosphonates; Double-Blind Method; Female; Humans; Imidazoles; Infusions, Intravenous; Knee Joint; Male; Middle Aged; Osteoarthritis, Knee; Outcome Assessment, Health Care; Pain Measurement; Treatment Outcome; Zoledronic Acid | 2012 |
Acute phase response following intravenous zoledronate in postmenopausal women with low bone mass.
Topics: Acute-Phase Reaction; Bone and Bones; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Imidazoles; Injections, Intravenous; Logistic Models; Middle Aged; Organ Size; Postmenopause; Zoledronic Acid | 2012 |
Monocytes and γδ T cells control the acute-phase response to intravenous zoledronate: insights from a phase IV safety trial.
Topics: Acute-Phase Reaction; Administration, Intravenous; Cohort Studies; Cytokines; Diphosphonates; Flow Cytometry; Humans; Imidazoles; Lymphocyte Activation; Monocytes; T-Lymphocytes; Zoledronic Acid | 2013 |
Acute phase response and mineral status following low dose intravenous zoledronic acid in children.
Topics: Acute-Phase Reaction; Adolescent; Bone Density Conservation Agents; Bone Diseases; C-Reactive Protein; Calcium; Child; Child, Preschool; Diphosphonates; Dose-Response Relationship, Drug; Female; Humans; Hypocalcemia; Imidazoles; Infusions, Intravenous; Male; Parathyroid Hormone; Phosphates; Zoledronic Acid | 2007 |
An in vitro and in vivo study of cytokines in the acute-phase response associated with bisphosphonates.
Topics: Acute-Phase Reaction; Adult; Bone Diseases; Carrier Proteins; Clodronic Acid; Diphosphonates; Female; Humans; Imidazoles; Injections, Intravenous; Interleukin-1; Interleukin-6; Leukocyte Count; Male; Middle Aged; Pamidronate; Tumor Necrosis Factor-alpha; Zoledronic Acid | 1997 |
22 other study(ies) available for zoledronic acid and Acute-Phase Reaction
| Article | Year |
|---|---|
Predicting the acute-phase response fever risk in bisphosphonate-naive osteoporotic patients receiving their first dose of zoledronate.
Topics: Acute-Phase Reaction; Calcium; Diphosphonates; Humans; Retrospective Studies; Vitamin D; Zoledronic Acid | 2022 |
Association between vitamin D and zoledronate-induced acute-phase response fever risk in osteoporotic patients.
Topics: Acute-Phase Reaction; Calcitonin; Humans; Retrospective Studies; Vitamin D; Vitamins; Zoledronic Acid | 2022 |
The impact of acute-phase reaction on mortality and re-fracture after zoledronic acid in hospitalized elderly osteoporotic fracture patients.
Topics: Acute-Phase Reaction; Aged; Bone Density Conservation Agents; Humans; Middle Aged; Osteoporotic Fractures; Retrospective Studies; Zoledronic Acid | 2023 |
Zoledronic acid-induced severe lymphopenia.
Topics: Acute-Phase Reaction; Anemia; Bone Density Conservation Agents; Diphosphonates; Humans; Imidazoles; Infusions, Intravenous; Lymphopenia; Male; Osteoporosis; Thrombocytopenia; Zoledronic Acid | 2023 |
Addition of dexamethasone to manage acute phase responses following initial zoledronic acid infusion.
Topics: Acute-Phase Reaction; Bone Density Conservation Agents; Dexamethasone; Diphosphonates; Female; Humans; Imidazoles; Osteoporosis, Postmenopausal; Zoledronic Acid | 2021 |
Zoledronate promotes inflammatory cytokine expression in human CD14-positive monocytes among peripheral mononuclear cells in the presence of γδ T cells.
Topics: Acute-Phase Reaction; Bone Density Conservation Agents; Cells, Cultured; Coculture Techniques; Cytokines; Humans; Inflammation Mediators; Intraepithelial Lymphocytes; Lipopolysaccharide Receptors; Lymphocyte Activation; Monocytes; Zoledronic Acid | 2021 |
Multicenter Study on Observation of Acute-phase Responses After Infusion of Zoledronic Acid 5 mg in Chinese Women with Postmenopausal Osteoporosis.
Topics: Acute-Phase Reaction; Aged; Anti-Inflammatory Agents, Non-Steroidal; Bone Density Conservation Agents; China; Diphosphonates; Female; Humans; Imidazoles; Incidence; Infusions, Intravenous; Middle Aged; Osteoporosis, Postmenopausal; Pain; Product Surveillance, Postmarketing; Zoledronic Acid | 2017 |
ACUTE PHASE REACTIONS AFTER ZOLEDRONIC ACID INFUSION: PROTECTIVE ROLE OF 25-HYDROXYVITAMIN D AND PREVIOUS ORAL BISPHOSPHONATE THERAPY.
Topics: Acute-Phase Reaction; Administration, Oral; Aged; Bone Density Conservation Agents; Case-Control Studies; Diphosphonates; Female; Humans; Imidazoles; Infusions, Intravenous; Middle Aged; Odds Ratio; Osteoporosis, Postmenopausal; Prospective Studies; Protective Factors; Vitamin D; Zoledronic Acid | 2018 |
Adrenal crisis after first infusion of zoledronic acid: a case report.
Topics: Acute Disease; Acute-Phase Reaction; Addison Disease; Aged, 80 and over; Bone Density Conservation Agents; Female; Humans; Hydrocortisone; Osteoporosis, Postmenopausal; Zoledronic Acid | 2018 |
Acute-phase reaction induced by zoledronate and its effect on prognosis of patients with advanced non-small cell lung cancer.
Topics: Acute-Phase Reaction; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Cell Count; Female; Follow-Up Studies; Humans; Lung Neoplasms; Lymphocyte Activation; Male; Middle Aged; Prognosis; Receptors, Antigen, T-Cell, gamma-delta; Retrospective Studies; Survival Analysis; T-Lymphocytes; Zoledronic Acid | 2018 |
Acute phase response after zoledronic acid is associated with long-term effects on white blood cells.
Topics: Acute-Phase Reaction; Administration, Oral; Aged; Aged, 80 and over; Bone Density Conservation Agents; Diphosphonates; Eosinophils; Female; Humans; Imidazoles; Leukocyte Count; Leukocytes; Lymphocytes; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Receptors, Antigen, T-Cell, gamma-delta; T-Lymphocyte Subsets; Time Factors; Zoledronic Acid | 2013 |
[Risk factors of acute-phase response following the first-dose administration of zoledronic acid in the treatment of osteoporosis].
Topics: Acid Phosphatase; Acute-Phase Reaction; Aged; Diphosphonates; Female; Humans; Imidazoles; Isoenzymes; Male; Middle Aged; Osteoporosis; Risk Factors; Tartrate-Resistant Acid Phosphatase; Zoledronic Acid | 2013 |
Cytokines and insulin resistance after zoledronic acid-induced acute phase response.
Topics: Acute-Phase Reaction; Adiponectin; Bone Density Conservation Agents; C-Reactive Protein; Diphosphonates; Female; Humans; Hydrocortisone; Imidazoles; Insulin Resistance; Interleukin-6; Leptin; Middle Aged; Osteoporosis, Postmenopausal; Resistin; Tumor Necrosis Factor-alpha; Zoledronic Acid | 2014 |
Gamma-delta T lymphocytes and 25-hydroxy vitamin D levels as key factors in autoimmunity and inflammation: the case of zoledronic acid-induced acute phase reaction.
Topics: Acute-Phase Reaction; Aged; Aged, 80 and over; Autoimmunity; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Imidazoles; Middle Aged; Osteoporosis; Receptors, Antigen, T-Cell, gamma-delta; T-Lymphocyte Subsets; Th1 Cells; Vitamin D; Zoledronic Acid | 2015 |
Short-Term Safety of Zoledronic Acid in Young Patients With Bone Disorders: An Extensive Institutional Experience.
Topics: Acute-Phase Reaction; Adolescent; Alkaline Phosphatase; Bone Density Conservation Agents; Bone Diseases; Calcitriol; Calcium; Child; Child, Preschool; Diphosphonates; Female; Humans; Hypercalcemia; Hypocalcemia; Hypophosphatemia; Imidazoles; Infant; Male; Osteogenesis Imperfecta; Osteoporosis; Prospective Studies; Retrospective Studies; Risk Factors; Young Adult; Zoledronic Acid | 2015 |
Severe acute phase response after intravenous zoledronic acid in adult patients with cerebral palsy.
Topics: Acute-Phase Reaction; Adolescent; Adult; Aged; Cerebral Palsy; Diphosphonates; Humans; Imidazoles; Infusions, Intravenous; Severity of Illness Index; Young Adult; Zoledronic Acid | 2016 |
Factors associated with acute-phase response of bisphosphonate-naïve or pretreated women with osteoporosis receiving an intravenous first dose of zoledronate or ibandronate.
Topics: Acute-Phase Reaction; Aged; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Middle Aged; Osteoporosis, Postmenopausal; Prospective Studies; Risk Factors; Severity of Illness Index; Zoledronic Acid | 2017 |
Circulating γδ T cells and the risk of acute-phase response after zoledronic acid administration.
Topics: Acute-Phase Reaction; Aged; Aged, 80 and over; Bone Density Conservation Agents; Cell Movement; Diphosphonates; Female; Humans; Imidazoles; Male; Middle Aged; Receptors, Antigen, T-Cell, gamma-delta; Risk Factors; Zoledronic Acid | 2012 |
The role of cytokines and adipocytokines in zoledronate-induced acute phase reaction in postmenopausal women with low bone mass.
Topics: Acute-Phase Reaction; Adipokines; Age Factors; Aged; Bone Density; Bone Density Conservation Agents; Cytokines; Diphosphonates; Female; Humans; Imidazoles; Insulin Resistance; Lymphocyte Count; Middle Aged; Nicotinamide Phosphoribosyltransferase; Osteoporosis, Postmenopausal; Postmenopause; Risk Factors; Zoledronic Acid | 2012 |
Intravenous bisphosphonates for postmenopausal osteoporosis: safety profiles of zoledronic acid and ibandronate in clinical practice.
Topics: Acute-Phase Reaction; Aged; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; Female; Humans; Ibandronic Acid; Imidazoles; Incidence; Infusions, Intravenous; Injections, Intravenous; Middle Aged; Osteoporosis, Postmenopausal; Retrospective Studies; Zoledronic Acid | 2013 |
Fever after zoledronic acid administration is due to increase in TNF-alpha and IL-6.
Topics: Acute-Phase Reaction; Adult; Aged; Aged, 80 and over; Bone Neoplasms; Bone Resorption; Calcium; Diphosphonates; Female; Fever; Humans; Imidazoles; Interferon-gamma; Interleukin-6; Male; Middle Aged; Tumor Necrosis Factor-alpha; Zoledronic Acid | 2003 |
A hitherto unreported high incidence of zoledronic acid-induced acute phase reaction in patients with cancer treatment-induced bone loss.
Topics: Acute-Phase Reaction; Aromatase Inhibitors; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Humans; Imidazoles; Incidence; Osteoporosis; Zoledronic Acid | 2007 |